. At week 00, LS mean (00% CI) difference, vs tramadol, in LBPI was −0.00 (−0.00 to 0.00; *P* = 0.0000) for tanezumab 00 mg and −0.00 (−0.00 to 0.00; *P* = 0.0000) for tanezumab 0 mg. The percentage of patients achieving ≥00% improvement in LBPI at week 00 was greater in the tanezumab 0 mg (00.0%) and tanezumab 00 mg (00.0%) groups compared to 